A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This study is looking to determine the maximum tolerated dose (MTD) and recommended phase 2
dose (RP2D) of lyso-thermosensitive liposomal doxorubicin (LTLD) administered in combination
with MR-HIFU in children with relapsed/refractory solid tumors, which may include but are not
limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma family of tumors,
osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, and germ cell tumors.